176 related articles for article (PubMed ID: 9424089)
1. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals.
Hertl M; Amagai M; Sundaram H; Stanley J; Ishii K; Katz SI
J Invest Dermatol; 1998 Jan; 110(1):62-6. PubMed ID: 9424089
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals.
Hertl M; Karr RW; Amagai M; Katz SI
J Invest Dermatol; 1998 Apr; 110(4):388-92. PubMed ID: 9540980
[TBL] [Abstract][Full Text] [Related]
3. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris.
Veldman C; Höhne A; Dieckmann D; Schuler G; Hertl M
J Immunol; 2004 May; 172(10):6468-75. PubMed ID: 15128839
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.
Hertl M; Riechers R
J Dermatol; 1999 Nov; 26(11):748-52. PubMed ID: 10635617
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.
Eming R; Hennerici T; Bäcklund J; Feliciani C; Visconti KC; Willenborg S; Wohde J; Holmdahl R; Sønderstrup G; Hertl M
J Immunol; 2014 Nov; 193(9):4391-9. PubMed ID: 25252957
[TBL] [Abstract][Full Text] [Related]
6. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles.
Veldman C; Stauber A; Wassmuth R; Uter W; Schuler G; Hertl M
J Immunol; 2003 Jan; 170(1):635-42. PubMed ID: 12496453
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.
Lin MS; Swartz SJ; Lopez A; Ding X; Fernandez-Vina MA; Stastny P; Fairley JA; Diaz LA
J Clin Invest; 1997 Jan; 99(1):31-40. PubMed ID: 9011573
[TBL] [Abstract][Full Text] [Related]
8. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice.
Aoki-Ota M; Tsunoda K; Ota T; Iwasaki T; Koyasu S; Amagai M; Nishikawa T
Br J Dermatol; 2004 Aug; 151(2):346-54. PubMed ID: 15327541
[TBL] [Abstract][Full Text] [Related]
9. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.
Lin MS; Swartz SJ; Lopez A; Ding X; Fairley JA; Diaz LA
J Invest Dermatol; 1997 Dec; 109(6):734-7. PubMed ID: 9406813
[TBL] [Abstract][Full Text] [Related]
10. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease.
Rizzo C; Fotino M; Zhang Y; Chow S; Spizuoco A; Sinha AA
Clin Exp Dermatol; 2005 Sep; 30(5):535-40. PubMed ID: 16045688
[TBL] [Abstract][Full Text] [Related]
11. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris.
Didona D; Scarsella L; Hudemann C; Volkmann K; Zimmer CL; Beckert B; Tikkanen R; Korff V; Kühn K; Wienzek-Lischka S; Bein G; Di Zenzo G; Böhme J; Cunha T; Solimani F; Pieper J; Juratli HA; Göbel M; Schmidt T; Borradori L; Yazdi AS; Sitaru C; Garn H; Eming R; Fleischer S; Hertl M
J Invest Dermatol; 2024 Feb; 144(2):263-272.e8. PubMed ID: 37717934
[TBL] [Abstract][Full Text] [Related]
12. Characterization of desmoglein-3 epitope region peptides as synthetic antigens: analysis of their in vitro T cell stimulating efficacy, cytotoxicity, stability, and their conformational features.
Szabados H; Uray K; Majer Z; Silló P; Kárpáti S; Hudecz F; Bősze S
J Pept Sci; 2015 Sep; 21(9):731-42. PubMed ID: 26250896
[TBL] [Abstract][Full Text] [Related]
13. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals.
Veldman CM; Gebhard KL; Uter W; Wassmuth R; Grötzinger J; Schultz E; Hertl M
J Immunol; 2004 Mar; 172(6):3883-92. PubMed ID: 15004196
[TBL] [Abstract][Full Text] [Related]
14. T cell receptor gene usage in desmoglein-3-specific T lymphocytes from patients with pemphigus vulgaris.
Hacker-Foegen MK; Fairley JA; Lin MS
J Invest Dermatol; 2003 Dec; 121(6):1365-72. PubMed ID: 14675184
[TBL] [Abstract][Full Text] [Related]
15. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris.
Schmidt T; Willenborg S; Hünig T; Deeg CA; Sonderstrup G; Hertl M; Eming R
Exp Dermatol; 2016 Apr; 25(4):293-8. PubMed ID: 26661498
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to the amino-terminal domain of desmoglein 1 are retained during transition from pemphigus vulgaris to pemphigus foliaceus.
España A; Koga H; Suárez-Fernández R; Ohata C; Ishii N; Irarrazaval I; Teye K; Ohyama B; Hashimoto T
Eur J Dermatol; 2014; 24(2):174-9. PubMed ID: 24776707
[TBL] [Abstract][Full Text] [Related]
17. A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes.
Aoyama Y; Owada MK; Kitajima Y
Eur J Immunol; 1999 Jul; 29(7):2233-40. PubMed ID: 10427986
[TBL] [Abstract][Full Text] [Related]
18. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1.
Hashimoto T; Amagai M; Garrod DR; Nishikawa T
Epithelial Cell Biol; 1995; 4(2):63-9. PubMed ID: 8688919
[TBL] [Abstract][Full Text] [Related]
19. Role of intramolecular epitope spreading in pemphigus vulgaris.
Salato VK; Hacker-Foegen MK; Lazarova Z; Fairley JA; Lin MS
Clin Immunol; 2005 Jul; 116(1):54-64. PubMed ID: 15925832
[TBL] [Abstract][Full Text] [Related]
20. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris.
Müller R; Svoboda V; Wenzel E; Müller HH; Hertl M
Exp Dermatol; 2008 Jan; 17(1):35-43. PubMed ID: 18095943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
